Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21731344 | 1.00 | MCHR1 (0.41) | MCHR1KCNH2CNR1CNR2NOS3 | |
| SCHEMBL22375312 | 0.82 | KCNH2 (0.41) | KCNH2CNR1CNR2NOS3NOS2 | |
| SCHEMBL26326025 | 0.82 | KCNH2 (0.41) | KCNH2CNR1CNR2NOS3NOS2 | |
| SCHEMBL22624105 | 0.79 | KCNH2 (0.39) | KCNH2CNR1CNR2TLR8IDH1 | |
| SCHEMBL21064262 | 0.79 | KCNH2 (0.39) | KCNH2CNR1CNR2TLR8 | |
| Undecane SCHEMBL28275328 | 0.78 | KCNH2 (0.54) | MCHR1KCNH2NOS3NOS2TLR8 | |
| SCHEMBL23745402 | 0.78 | KCNH2 (0.38) | KCNH2CNR1CNR2 | |
| SCHEMBL19964027 | 0.77 | CDK2 (0.32) | MCHR1CNR1CNR2TLR8 | |
| SCHEMBL19963987 | 0.77 | CDK2 (0.32) | MCHR1CNR1CNR2TLR8 | |
| SCHEMBL22375286 | 0.76 | KCNH2 (0.39) | KCNH2CNR1CNR2NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055844-A1 | 4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055844-A1 | 4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES FOR INCREASING CFTR ACTIVITY | CFTR, CLIC4, SCNN1B | MCHR1 4633/4885KCNH2 1203/4885CNR1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.